

haloalkyl, C_{3-5} cycloalkyl, and 4-5 membered heterocyclyl; and

each $\mathbf{R^h}$ is independently selected from the group consisting of: halo, cyano, -OH, -C_{1-6} alkoxy, -C_{1-6} haloalkoxy, -NH_2, -N(H)(C_{1-3} alkyl), and -N(C_{1-3} alkyl)$_2$-.


In one aspect, the present disclosure provides a compound of Formula (**II-a6**), (**II-a7**), (**II-a4**), (**II-a5**), or (**II-a8**):




Formula (**II-a6**)




Formula (**II-a7**)



Formula (**II-a4**)



Formula (**II-a5**)



Formula (**II-a8**)

or a pharmaceutically acceptable salt thereof, wherein:

$\mathbf{R^7}$ is C_{1-3} alkyl substituted with -OH or C_{1-3} alkoxy;

$\mathbf{R^{7a}}$ is C_{1-3} alkyl substituted with -OH;

$\mathbf{R^{7b}}$ is selected from the group consisting of:

C_{1-3} alkyl optionally substituted with 1-3 F, and

C_{1-3} alkyl substituted with -OH or C_{1-3} alkoxy;

b4 is 0;

each $\mathbf{R^{10}}$ is independently selected from the group consisting of: -Cl, -F, -CN, and C_{1-3} alkyl optionally substituted with 1-3 $\mathbf{R^c}$;


$\mathbf{X^1}$ is CH_2;

$\mathbf{X^2}$ is CH_2;

$\mathbf{X^3}$ is $CH\mathbf{R^L}$;

$\mathbf{R^L}$ is selected from the group consisting of C_{1-3} alkoxy, -F, CN, and C_{1-3} alkyl optionally substituted with 1-3 $\mathbf{R^c}$;

$\mathbf{Y^2}$ is $-CH_2-$;

$\mathbf{R^3}$ is  optionally substituted with 1-2 substituents each independently selected from the group consisting of: -F, $-C_{1-3}$ alkoxy, and $-C_{1-3}$ haloalkoxy;


each $\mathbf{R^c}$ is independently selected from the group consisting of: halo, cyano, -OH, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-N\mathbf{R^d}\mathbf{R^e}$, $C(=O)C_{1-6}$ alkyl, $C(=O)C_{1-6}$ haloalkyl, $C(=O)OC_{1-6}$ alkyl, $C(=O)OC_{1-6}$ haloalkyl, C(=O)OH, $C(=O)N(\mathbf{R^f})_2$, $S(O)_{0-2}(C_{1-6}$ alkyl), $S(O)_{0-2}(C_{1-6}$ haloalkyl), and $S(O)_{1-2}N(\mathbf{R^f})_2$;

each $\mathbf{R^d}$ and $\mathbf{R^e}$ is independently selected from the group consisting of: H, $C(=O)C_{1-6}$ alkyl, $C(=O)C_{1-6}$ haloalkyl, $C(=O)OC_{1-6}$ alkyl, $C(=O)OC_{1-6}$ haloalkyl, $C(=O)N(\mathbf{R^f})_2$, $S(O)_{1-2}(C_{1-6}$ alkyl), $S(O)_{1-2}(C_{1-6}$ haloalkyl), $S(O)_{1-2}N(\mathbf{R^f})_2$, and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each $\mathbf{R^f}$ is independently selected from the group consisting of: H and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$; and

each $\mathbf{R^h}$ is independently selected from the group consisting of: halo, cyano, -OH, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-NH_2$, $-N(H)(C_{1-3}$ alkyl), and $-N(C_{1-3}$ alkyl$)_{2-}$.

In another aspect, the present disclosure provides a compound of Formula (**II-a3**):



Formula (**II-a3**)

or a pharmaceutically acceptable salt thereof, wherein:

b4 is 0;

each $\mathbf{R^{10}}$ is independently selected from the group consisting of: -Cl, -F, -CN, and C_{1-3} alkyl optionally substituted with 1-3 $\mathbf{R^c}$;

$\mathbf{R^{7a}}$ is $C(=O)N(Me)_2$;


$\mathbf{R^{7b}}$ is -halo or C_{1-3} alkyl;

$\mathbf{X^1}$ is CH_2;

$\mathbf{X^2}$ and $\mathbf{X^3}$ are independently selected from the group consisting of: CH_2, $CH\mathbf{R^L}$, $C(\mathbf{R^L})_2$, provided that 1-2 of $\mathbf{X^2}$ and $\mathbf{X^3}$ is independently $CH\mathbf{R^L}$ or $C(\mathbf{R^L})_2$;

$\mathbf{R^L}$ is selected from the group consisting of C_{1-3} alkoxy, -F, CN, and C_{1-3} alkyl optionally substituted with 1-3 $\mathbf{R^c}$;

$\mathbf{Y^2}$ is $-CH_2-$;

$\mathbf{R^3}$ is  optionally substituted with 1-2 substituents each independently selected from the group consisting of: -F, $-C_{1-3}$ alkoxy, and $-C_{1-3}$ haloalkoxy;


each $\mathbf{R^c}$ is independently selected from the group consisting of: halo, cyano, -OH, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-N\mathbf{R^d}\mathbf{R^e}$, $C(=O)C_{1-6}$ alkyl, $C(=O)C_{1-6}$ haloalkyl, $C(=O)OC_{1-6}$ alkyl, $C(=O)OC_{1-6}$ haloalkyl, C(=O)OH, $C(=O)N(\mathbf{R^f})_2$, $S(O)_{0-2}(C_{1-6}$ alkyl), $S(O)_{0-2}(C_{1-6}$ haloalkyl), and $S(O)_{1-2}N(\mathbf{R^f})_2$;

each $\mathbf{R^d}$ and $\mathbf{R^e}$ is independently selected from the group consisting of: H, $C(=O)C_{1-6}$ alkyl, $C(=O)C_{1-6}$ haloalkyl, $C(=O)OC_{1-6}$ alkyl, $C(=O)OC_{1-6}$ haloalkyl, $C(=O)N(\mathbf{R^f})_2$, $S(O)_{1-2}(C_{1-6}$ alkyl), $S(O)_{1-2}(C_{1-6}$ haloalkyl), $S(O)_{1-2}N(\mathbf{R^f})_2$, and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each **R^{f}** is independently selected from the group consisting of: H and C_{1-6} alkyl optionally substituted with 1-3 **R^{h}**; and

each **R^{h}** is independently selected from the group consisting of: halo, cyano, -OH, -C_{1-6} alkoxy, -C_{1-6} haloalkoxy, -NH_2, -N(H)(C_{1-3} alkyl), and -N(C_{1-3} alkyl)$_2$-.

Also provided herein are compounds of Formula (**III**):




Formula (**III**)

or pharmaceutically acceptable salts thereof, wherein:

R^{1} is selected from the group consisting of:

(i) a 4-10 membered heterocyclyl optionally substituted with 1-4 **R^{7}**;

(ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and $S(O)_2NH$, and wherein the heterocyclyl is further optionally substituted with 1-3 **R^{7}** at one or more ring carbon atoms; and

(iii) 

, wherein **b2** is 0, 1, 2, or 3; and **A^{1}** and **A^{2}** are independently selected from the group consisting of: N, CH, and C**R^{7}**;

each **R^{7}** is independently selected from the group consisting of **R^{a}** and **R^{b}**;

X^{1} is selected from the group consisting of a bond, $S(O)_{0-2}$, CH_2, CH**R^{L}**, C(**R^{L}**)$_2$, and O;

X^{2} and **X^{3}** are independently selected from the group consisting of: CH_2, CH**R^{L}**, C(**R^{L}**)$_2$, O, and $S(O)_{0-2}$, provided that no more than one of **X^{1}**, **X^{2}**, and **X^{3}** is selected from the group consisting of: O and $S(O)_{0-2}$;

R^{9} is selected from the group consisting of: H, N**R^{d}R^{e}**, -OH, and halo;

b4 is 0 or 1;

R^{10} is selected from the group consisting of **R^{a}** and **R^{b}**;

each $\mathbf{R^c}$ is independently selected from the group consisting of: halo, cyano, -OH, -C_{1-6} alkoxy, -C_{1-6} haloalkoxy, -N$\mathbf{R^d}\mathbf{R^e}$, C(=O)C_{1-6} alkyl, C(=O)C_{1-6} haloalkyl, C(=O)OC_{1-6} alkyl, C(=O)OC_{1-6} haloalkyl, C(=O)OH, C(=O)N($\mathbf{R^f}$)$_2$, S(O)$_{0-2}$(C_{1-6} alkyl), S(O)$_{0-2}$(C_{1-6} haloalkyl), and S(O)$_{1-2}$N($\mathbf{R^f}$)$_2$;

each $\mathbf{R^d}$ and $\mathbf{R^e}$ is independently selected from the group consisting of: H, C(=O)C_{1-6} alkyl, C(=O)C_{1-6} haloalkyl, C(=O)OC_{1-6} alkyl, C(=O)OC_{1-6} haloalkyl, C(=O)N($\mathbf{R^f}$)$_2$, S(O)$_{1-2}$(C_{1-6} alkyl), S(O)$_{1-2}$(C_{1-6} haloalkyl), S(O)$_{1-2}$N($\mathbf{R^f}$)$_2$, and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each $\mathbf{R^f}$ is independently selected from the group consisting of: H and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each $\mathbf{R^g}$ is independently selected from the group consisting of: $\mathbf{R^h}$, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-5} cycloalkyl, and 4-5 membered heterocyclyl; and

each $\mathbf{R^h}$ is independently selected from the group consisting of: halo, cyano, -OH, -C_{1-6} alkoxy, -C_{1-6} haloalkoxy, -NH_2, -N(H)(C_{1-3} alkyl), and -N(C_{1-3} alkyl)$_2$-.

Also provided herein are pharmaceutical compositions comprising a compound of Formula (**II**) (e.g., Formula (**II-a**), (**II-b**), (**II-a1**), (**II-b1**), (**II-a2**), (**II-b2**), (**II-3**), (**II-a3**), (**II-4**), (**II-a4**), (**II-5**), (**II-a5**), (**II-6**), (**II-a6**), (**II-7**), (**II-a7**), (**II-7**), or (**II-a8**)), Formula (**III**) (e.g., Formula (**III-1**), (**III-2**), (**III-3**), (**III-4**), (**III-5**), (**III-6**), (**III-7**), or (**III-8**)), Formula (**IV**) (e.g., Formula (**IV-a**), (**IV-b**), (**IV-c**), (**IV-a1)**, (**IV-b1**), (**IV-a2**), (**IV-b2**), (**IV-a3**), (**IV-b3**), (**IV-a4**), (**IV-b4**), (**IV-a5**), (**IV-b5**), (**IV-a6**), (**IV-b6**), (**IV-a7**), (**IV-b7**), (**IV-a8**), or (**IV-b8**)), Formula (**V**) (e.g., Formula (**V-a**) or (**V-b**), (**V-a1)**, (**V-c**), (**V-d**), (**V-b1**), (**V-a2**), (**V-b2**), (**V-a3**), or (**V-b3**)), Formula (**VI**) (e.g., Formula (**VI-a**), (**VI-b**), (**VI-c**), (**VI-d**), or (**VI-e**))), or Formula (**A**) (e.g., Formula (**I-a1**)), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

In one aspect, the present disclosure provides a pharmaceutical composition comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Provided herein are methods for treating cancer in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount a compound of Formula (**II**) (e.g., Formula (**II-a**), (**II-b**), (**II-a1**), (**II-b1**), (**II-a2**), (**II-b2**), (**II-3**), (**II-a3**), (**II-4**), (**II-a4**), (**II-5**), (**II-a5**), (**II-6**), (**II-a6**), (**II-7**), (**II-a7**), (**II-7**), or (**II-a8**)), Formula (**III**) (e.g., Formula (**III-1**), (**III-2**), (**III-3**), (**III-4**), (**III-5**), (**III-6**), (**III-7**), or (**III-8**)), Formula (**IV**) (e.g., Formula (**IV-a**), (**IV-b**), (**IV-c**), (**IV-a1)**, (**IV-b1**), (**IV-a2**), (**IV-b2**), (**IV-a3**), (**IV-b3**), (**IV-a4**), (**IV-b4**), (**IV-a5**), (**IV-b5**), (**IV-a6**), (**IV-b6**), (**IV-a7**), (**IV-b7**), (**IV-a8**), or (**IV-b8**)),

(**V-a2**), (**V-b2**), (**V-a3**), or (**V-b3**)), Formula (**VI**) (e.g., Formula (**VI-a**), (**VI-b**), (**VI-c**), (**VI-d**), or (**VI-e**))), or Formula (**A**) (e.g., Formula (**I-a1**)), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein.

This disclosure also provides methods of treating a KRas-associated cancer (e.g., a mutant KRas-associated cancer (e.g., a KRas G12A-associated cancer, a KRas G12C-associated cancer, a KRas G12D-associated cancer, a KRas G12R-associated cancer, a KRas G12S-associated cancer, or a KRas G12V-associated cancer)) in a subject, the methods comprising: determining that the cancer in the subject has a KRas dysregulation (e.g., a KRas G12A-associated cancer, a KRas G12C-associated cancer, a KRas G12D-associated cancer, a KRas G12R-associated cancer, a KRas G12S-associated cancer, or a KRas G12V-associated cancer)); and administering to the subject a therapeutically effective amount of a compound of Formula (**II**) (e.g., Formula (**II-a**), (**II-b**), (**II-a1**), (**II-b1**), (**II-a2**), (**II-b2**), (**II-3**), (**II-a3**), (**II-4**), (**II-a4**), (**II-5**), (**II-a5**), (**II-6**), (**II-a6**), (**II-7**), (**II-a7**), (**II-7**), or (**II-a8**)), Formula (**III**) (e.g., Formula (**III-1**), (**III-2**), (**III-3**), (**III-4**), (**III-5**), (**III-6**), (**III-7**), or (**III-8**)), Formula (**IV**) (e.g., Formula (**IV-a**), (**IV-b**), (**IV-c**), (**IV-a1)**, (**IV-b1**), (**IV-a2**), (**IV-b2**), (**IV-a3**), (**IV-b3**), (**IV-a4**), (**IV-b4**), (**IV-a5**), (**IV-b5**), (**IV-a6**), (**IV-b6**), (**IV-a7**), (**IV-b7**), (**IV-a8**), or (**IV-b8**)), Formula (**V**) (e.g., Formula (**V-a**) or (**V-b**), (**V-a1)**, (**V-c**), (**V-d**), (**V-b1**), (**V-a2**), (**V-b2**), (**V-a3**), or (**V-b3**)), Formula (**VI**) (e.g., Formula (**VI-a**), (**VI-b**), (**VI-c**), (**VI-d**), or (**VI-e**))), or Formula (**A**) (e.g., Formula (**I-a1**)), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein.

In one aspect, the present disclosure provides a use of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition as disclosed herein, in the manufacture of a medicament for treating a cancer having a KRas dysregulation.


In another aspect, the present disclosure provides a compound as disclosed herein for use in therapy.

To facilitate understanding of the disclosure set forth herein, a number of terms are provided. Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described herein are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Each of the patents, applications, published applications, and other publications that are mentioned throughout the specification and the attached appendices are incorporated herein by reference in their entireties. In the case of conflict between the present disclosure and any content incorporated by reference, the present disclosure controls.


The details of one or more examples of the disclosure are set forth in the accompanying drawings and the description below. Other features and advantages of the disclosure will be apparent from the description and drawings, and from the claims.

WHAT IS CLAIMED IS:


1. A compound of Formula (**II-a6**), (**II-a7**), (**II-a4**), (**II-a5**), or (**II-a8**):




Formula (**II-a6**)




Formula (**II-a7**)



Formula (**II-a4**)



Formula (**II-a5**)



Formula (**II-a8**)

or a pharmaceutically acceptable salt thereof, wherein:

R^7 is C_{1-3} alkyl substituted with -OH or C_{1-3} alkoxy;

R^{7a} is C_{1-3} alkyl substituted with -OH;

R^{7b} is selected from the group consisting of:

C_{1-3} alkyl optionally substituted with 1-3 F, and

C_{1-3} alkyl substituted with -OH or C_{1-3} alkoxy;

b4 is 0;

each $\mathbf{R^{10}}$ is independently selected from the group consisting of: -Cl, -F, -CN, and C_{1-3} alkyl optionally substituted with 1-3 $\mathbf{R^c}$;


$\mathbf{X^1}$ is CH_2;

$\mathbf{X^2}$ is CH_2;

$\mathbf{X^3}$ is $CH\mathbf{R^L}$;

$\mathbf{R^L}$ is selected from the group consisting of C_{1-3} alkoxy, -F, CN, and C_{1-3} alkyl optionally substituted with 1-3 $\mathbf{R^c}$;

$\mathbf{Y^2}$ is $-CH_2-$;

$\mathbf{R^3}$ is  optionally substituted with 1-2 substituents each independently selected from the group consisting of: -F, $-C_{1-3}$ alkoxy, and $-C_{1-3}$ haloalkoxy;



each $\mathbf{R^c}$ is independently selected from the group consisting of: halo, cyano, -OH, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-N\mathbf{R^d}\mathbf{R^e}$, $C(=O)C_{1-6}$ alkyl, $C(=O)C_{1-6}$ haloalkyl, $C(=O)OC_{1-6}$ alkyl, $C(=O)OC_{1-6}$ haloalkyl, C(=O)OH, $C(=O)N(\mathbf{R^f})_2$, $S(O)_{0-2}(C_{1-6}$ alkyl), $S(O)_{0-2}(C_{1-6}$ haloalkyl), and $S(O)_{1-2}N(\mathbf{R^f})_2$;

each $\mathbf{R^d}$ and $\mathbf{R^e}$ is independently selected from the group consisting of: H, $C(=O)C_{1-6}$ alkyl, $C(=O)C_{1-6}$ haloalkyl, $C(=O)OC_{1-6}$ alkyl, $C(=O)OC_{1-6}$ haloalkyl, $C(=O)N(\mathbf{R^f})_2$, $S(O)_{1-2}(C_{1-6}$ alkyl), $S(O)_{1-2}(C_{1-6}$ haloalkyl), $S(O)_{1-2}N(\mathbf{R^f})_2$, and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each $\mathbf{R^f}$ is independently selected from the group consisting of: H and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$; and



each $\mathbf{R^h}$ is independently selected from the group consisting of: halo, cyano, -OH, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-NH_2$, -N(H)(C_{1-3} alkyl), and $-N(C_{1-3}$ alkyl$)_{2-}$.

2. The compound of claim 1, wherein the compound is a compound of Formula (**II-a6**), or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or 2, wherein the  moiety is , and wherein $\mathbf{R^7}$ is C_{1-3} alkyl substituted with -OH.

4. The compound of claim 3, wherein $\mathbf{R^7}$ is -CH_2OH.

5. The compound of claim 1, wherein the compound is a compound of Formula (**II-a7**), or a pharmaceutically acceptable salt thereof.




6. The compound of claim 1 or 5, wherein the  moiety is .


7. The compound of claim 6, wherein $\mathbf{R^{7a}}$ is -CH_2OH, and $\mathbf{R^{7b}}$ is $C_{1\text{-}3}$ alkyl optionally substituted with 1-3 -F; optionally wherein $\mathbf{R^{7b}}$ is methyl.


8. The compound of claim 1, wherein the compound is a compound of Formula (**II-a4**), or a pharmaceutically acceptable salt thereof.



9. The compound of claim 1, wherein the compound is a compound of Formula (**II-a5**), or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, wherein the compound is a compound of Formula (**II-a8**), or a pharmaceutically acceptable salt thereof.

11. The compound of any one of claims 1-10, wherein $\mathbf{R^3}$ is , , or .


12. The compound of any one of claims 1-11, wherein $\mathbf{R^3}$ is ; optionally


wherein $\mathbf{R^3}$ is  .


13. The compound of any one of claims 1-12, wherein the  moiety is  .


14. The compound of any one of claims 1-13, wherein $\mathbf{R^L}$ is selected from the group consisting of: CH_3, CF_3, CHF_2, and CH_2F; optionally wherein $\mathbf{R^L}$ is CH_3.


15. The compound of claim 1, wherein the compound is selected from the group consisting of:






































































































































































or a pharmaceutically acceptable salt thereof.

16. A compound of Formula (**II-a3**):



Formula (**II-a3**)

or a pharmaceutically acceptable salt thereof, wherein:

b4 is 0;

each $\mathbf{R^{10}}$ is independently selected from the group consisting of: -Cl, -F, -CN, and C_{1-3} alkyl optionally substituted with 1-3 $\mathbf{R^c}$;

$\mathbf{R^{7a}}$ is $C(=O)N(Me)_2$;


$\mathbf{R^{7b}}$ is -halo or C_{1-3} alkyl;

$\mathbf{X^1}$ is CH_2;

$\mathbf{X^2}$ and $\mathbf{X^3}$ are independently selected from the group consisting of: CH_2, $CH\mathbf{R^L}$, $C(\mathbf{R^L})_2$, provided that 1-2 of $\mathbf{X^2}$ and $\mathbf{X^3}$ is independently $CH\mathbf{R^L}$ or $C(\mathbf{R^L})_2$;

$\mathbf{R^L}$ is selected from the group consisting of C_{1-3} alkoxy, -F, CN, and C_{1-3} alkyl optionally substituted with 1-3 $\mathbf{R^c}$;

$\mathbf{Y^2}$ is $-CH_2-$;

$\mathbf{R^3}$ is  optionally substituted with 1-2 substituents each independently selected from the group consisting of: -F, $-C_{1-3}$ alkoxy, and $-C_{1-3}$ haloalkoxy;

each $\mathbf{R^c}$ is independently selected from the group consisting of: halo, cyano, -OH, -C_{1-6} alkoxy, -C_{1-6} haloalkoxy, -N$\mathbf{R^d}\mathbf{R^e}$, C(=O)C_{1-6} alkyl, C(=O)C_{1-6} haloalkyl, C(=O)OC_{1-6} alkyl, C(=O)OC_{1-6} haloalkyl, C(=O)OH, C(=O)N($\mathbf{R^f}$)$_2$, S(O)$_{0-2}$(C_{1-6} alkyl), S(O)$_{0-2}$(C_{1-6} haloalkyl), and S(O)$_{1-2}$N($\mathbf{R^f}$)$_2$;

each $\mathbf{R^d}$ and $\mathbf{R^e}$ is independently selected from the group consisting of: H, C(=O)C_{1-6} alkyl, C(=O)C_{1-6} haloalkyl, C(=O)OC_{1-6} alkyl, C(=O)OC_{1-6} haloalkyl, C(=O)N($\mathbf{R^f}$)$_2$, S(O)$_{1-2}$(C_{1-6} alkyl), S(O)$_{1-2}$(C_{1-6} haloalkyl), S(O)$_{1-2}$N($\mathbf{R^f}$)$_2$, and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each $\mathbf{R^f}$ is independently selected from the group consisting of: H and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$; and


each $\mathbf{R^h}$ is independently selected from the group consisting of: halo, cyano, -OH, -C_{1-6} alkoxy, -C_{1-6} haloalkoxy, -NH_2, -N(H)(C_{1-3} alkyl), and -N(C_{1-3} alkyl)$_2$-.


17. The compound of claim 16, wherein $\mathbf{R^L}$ is CF_3 or CH_3.

18. The compound of claim 16 or 17, wherein $\mathbf{R^L}$ is CH_3.




19. The compound of any one of claims 16-18, wherein $\mathbf{R^{7b}}$ is -Cl, -F, or methyl.


20. The compound of any one of claims 16-19, wherein $\mathbf{R^{7b}}$ is -Cl.


21. The compound of claim 20, wherein the 



moiety is 

.


22. The compound of any one of claims 16-21, wherein $\mathbf{R^3}$ is , , or .


23. The compound of any one of claims 16-22, wherein $\mathbf{R^3}$ is .


24. The compound of any one of claims 16-23, wherein $\mathbf{R^3}$ is .


25. The compound of any one of claims 16-24, wherein the  moiety is .


26. The compound of claim 16, wherein the compound of Formula (**II-a3**) is selected from the group consisting of:



























































or a pharmaceutically acceptable salt thereof.

27. A pharmaceutical composition comprising a compound of any one of claims 1-26, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

28. Use of a compound of any one of claims 1-26, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 27, in the manufacture of a medicament for treating a cancer having a KRas dysregulation.

29. The use of claim 28, wherein the KRas dysregulation is a KRas mutation; optionally

wherein the KRas mutation is a KRas G12A mutation, a KRas G12C mutation, a KRas G12D mutation, a KRas G12R mutation, a KRas G12S mutation, or a KRas G12V mutation; or

the KRas mutation is a KRas G12C mutation, a KRas G12D mutation, or a KRas G12V mutation.

30. The use of claim 28 or 29, wherein the cancer is selected from the group consisting of: a hematological cancer, a soft tissue cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, mucinous carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, urothelial cancer, uterine cancer, and a combination thereof; or

the cancer is selected from the group consisting of: a colon cancer, endometrial cancer, lung cancer, pancreatic cancer, and uterine cancer; or

the cancer is a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma);

the cancer is a colorectal cancer; or

the cancer is a lung cancer (e.g., non-small cell lung cancer); or

the cancer is an ovarian cancer; or

the cancer is selected from the group consisting of: a colorectal cancer, gastric cancer, gastroesophageal cancer, head and neck squamous carcinoma, or lung cancer (e.g., NSCLC).

31. The use of any one of claims 28-30, wherein the compound or pharmaceutical composition is to be used in combination with an additional therapy or therapeutic agent; optionally wherein the additional therapy or therapeutic agent is selected from the group consisting of Ras pathway targeted therapeutic agents, kinase-targeted therapeutics, mTORC1 inhibitors or degraders, YAP inhibitors or degraders, proteasome inhibitors or degraders, HSP90 inhibitors or degraders, farnesyl transferase inhibitors or degraders, PTEN inhibitors or degraders, signal transduction pathway inhibitors or degraders, checkpoint inhibitors, modulators of the apoptosis pathway, chemotherapeutics, angiogenesis-targeted therapies, immune-targeted agents, radiotherapy, and combinations thereof; or the additional therapy or therapeutic agent is selected from the group consisting of kinase-targeted therapeutics (e.g., an EGFR inhibitor or a HER2 inhibitor), checkpoint inhibitors, chemotherapeutics, and immune-targeted agents.

32. A compound of any one of claims 1-26 for use in therapy.